For the applications of immunotherapy treatment based on pembrolizumab, P9 was selected as the best case, showing a positive therapeutic response with a remaining 40% of cell viability, while other patients (P13 was slightly significant) did not show significant sensitivity towards the biological treatment.
← all excerpts
In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening.
1
—
—